ZYMEWORKS INC (ZYME) Stock Price, Quote, News and Overview
NASDAQ:ZYME - Nasdaq - US98985Y1082 - Common Stock - Currency: USD
ZYME Quote, Performance and Key Statistics
12
-0.13 (-1.07%)
The current stock price of ZYME is 12 USD. In the past month the price decreased by -19.52%. In the past year, price increased by 4.9%.
ZYME Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About ZYME
Company Profile
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company is headquartered in Middletown, Delaware and currently employs 294 full-time employees. The company went IPO on 2019-06-24. The firm is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.
Company Info
ZYMEWORKS INC
108 Patriot Drive, Suite A
Middletown DELAWARE V6H 3V9 US
CEO: Ali Tehrani
Employees: 290
Company Website: https://www.zymeworks.com/
Investor Relations: https://ir.zymeworks.com/
Phone: 13022748744
ZYMEWORKS INC / ZYME FAQ
What is the stock price of ZYMEWORKS INC today?
The current stock price of ZYME is 12 USD. The price decreased by -1.07% in the last trading session.
What is the ticker symbol for ZYMEWORKS INC stock?
The exchange symbol of ZYMEWORKS INC is ZYME and it is listed on the Nasdaq exchange.
On which exchange is ZYME stock listed?
ZYME stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ZYMEWORKS INC stock?
14 analysts have analysed ZYME and the average price target is 20.85 USD. This implies a price increase of 73.72% is expected in the next year compared to the current price of 12. Check the ZYMEWORKS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ZYMEWORKS INC worth?
ZYMEWORKS INC (ZYME) has a market capitalization of 834.96M USD. This makes ZYME a Small Cap stock.
How many employees does ZYMEWORKS INC have?
ZYMEWORKS INC (ZYME) currently has 290 employees.
What are the support and resistance levels for ZYMEWORKS INC (ZYME) stock?
ZYMEWORKS INC (ZYME) has a support level at 10.43 and a resistance level at 14.48. Check the full technical report for a detailed analysis of ZYME support and resistance levels.
Is ZYMEWORKS INC (ZYME) expected to grow?
The Revenue of ZYMEWORKS INC (ZYME) is expected to decline by -1% in the next year. Check the estimates tab for more information on the ZYME EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ZYMEWORKS INC (ZYME) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ZYME, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ZYME, evaluating the profitability, health, valuation and growth aspects
- ZYMEWORKS INC (ZYME) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ZYMEWORKS INC (ZYME) Sales and EPS estimates to see what analysts future expectations are.
- ZYMEWORKS INC (ZYME) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ZYMEWORKS INC (ZYME) Insider and Institutional Ownership to learn about the owners and their transactions.
- ZYMEWORKS INC (ZYME) Stock Chart to make your own analysis
- ZYMEWORKS INC (ZYME) Latest news and press-releases to stay up to date.
Does ZYMEWORKS INC (ZYME) stock pay dividends?
ZYME does not pay a dividend.
When does ZYMEWORKS INC (ZYME) report earnings?
ZYMEWORKS INC (ZYME) will report earnings on 2025-04-30.
What is the Price/Earnings (PE) ratio of ZYMEWORKS INC (ZYME)?
ZYMEWORKS INC (ZYME) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.39).
What is the Short Interest ratio of ZYMEWORKS INC (ZYME) stock?
The outstanding short interest for ZYMEWORKS INC (ZYME) is 5.76% of its float. Check the ownership tab for more information on the ZYME short interest.
ZYME Technical Analysis
ZYME Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZYME. ZYME scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ZYME Financial Highlights
Over the last trailing twelve months ZYME reported a non-GAAP Earnings per Share(EPS) of -1.39. The EPS increased by 19.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.33% | ||
| ROE | -30.97% | ||
| Debt/Equity | 0 |
ZYME Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ZYME. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -25.65% and a revenue growth -1% for ZYME